Valneva: collaboration with Serum Institute of India
(CercleFinance.com) - Valneva announced Thursday that it has signed an exclusive licensing agreement for its chikungunya vaccine with the Serum Institute of India (SII), the world's largest vaccine manufacturer by number of doses.
The French group specifies that this collaboration is intended to increase the vaccine's accessibility in low- and middle-income countries (LMICs) in Asia.
In this respect, the laboratory had obtained funding of $41.3m from the Coalition for Epidemic Preparedness Innovations (CEPI), a package co-financed by the European Union.
Under the terms of the agreement, the two partners plan to work together to bring the vaccine to market in India and certain other Asian countries as quickly as possible, subject to local regulatory approvals.
This announcement comes as India is currently experiencing one of its worst chikungunya epidemics, with nearly 370.000 cases between January 2019 and July 2024.
As part of the collaboration, Valneva will transfer technology for the vaccine manufacturing process, while SII will be responsible for production and for obtaining and maintaining regulatory approval for the vaccine in India and other Asian countries.
The vaccine's future commercialisation will be based on a profit-sharing model, and Valneva will receive single-digit milestone payments of several million euros related to technology transfer and regulatory approvals.
Valneva's chikungunya vaccine is currently the world's first and only licensed vaccine against this disease.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The French group specifies that this collaboration is intended to increase the vaccine's accessibility in low- and middle-income countries (LMICs) in Asia.
In this respect, the laboratory had obtained funding of $41.3m from the Coalition for Epidemic Preparedness Innovations (CEPI), a package co-financed by the European Union.
Under the terms of the agreement, the two partners plan to work together to bring the vaccine to market in India and certain other Asian countries as quickly as possible, subject to local regulatory approvals.
This announcement comes as India is currently experiencing one of its worst chikungunya epidemics, with nearly 370.000 cases between January 2019 and July 2024.
As part of the collaboration, Valneva will transfer technology for the vaccine manufacturing process, while SII will be responsible for production and for obtaining and maintaining regulatory approval for the vaccine in India and other Asian countries.
The vaccine's future commercialisation will be based on a profit-sharing model, and Valneva will receive single-digit milestone payments of several million euros related to technology transfer and regulatory approvals.
Valneva's chikungunya vaccine is currently the world's first and only licensed vaccine against this disease.
Copyright (c) 2024 CercleFinance.com. All rights reserved.